{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:59:28Z","timestamp":1790812768120,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Even though the doravirine\/dolutegravir combination is not mentioned by guidelines, real-life data has begun to emerge on its use. We aimed to describe the durability of doravirine\/dolutegravir in a multicentre Italian cohort of elderly people with HIV (EPWH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included all EPWH who ever started the doravirine\/dolutegravir combination in six Italian centres and were followed up until treatment discontinuation (TD) for any reason (virological failure, death, treatment interruption for other reasons) on 31 March 2024. Descriptive statistics were used to describe the study population; Kaplan\u2013Meier curves and Cox regression analyses were used to estimate incidence and associated predictors of time to TD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 157 people; 61.1% were male, the median age was 59\u2005years (IQR: 55\u201364), 75.2% had multimorbidity, 38.9% were on polypharmacy, and 91.1% had HIV-RNA of &amp;lt;50\u2005copies\/mL. No genotype resistance test was available for 19.4% of people who started doravirine\/dolutegravir. The main reasons for starting doravirine\/dolutegravir were high cardiovascular risk (51.6%), simplification (52.9%) and drug\u2013drug interactions (25.5%). During a median follow-up of 27.85 (IQR: 22.92\u201331.79)\u2005months, 8 (5.1%) participants experienced TD (2 toxicities, 2 virological failures, 2 switches to long-acting drugs, 1 death and 1 transferred). The incidence of TD was 2.27 per 100 person-years of follow-up. Multivariable Cox regression analyses did not show any factors as predictors of TD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this multicentre cohort of EPWH with clinical complexity, the doravirine\/dolutegravir combination showed good durability over time. TD probability was very low, and no significant factors seem to predict it, likely due to the limited number and heterogeneity of cases of TD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf039","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:53:21Z","timestamp":1739188401000},"page":"1089-1096","source":"Crossref","is-referenced-by-count":5,"title":["Durability of doravirine\/dolutegravir dual combination in a multicentre cohort of elderly people with HIV"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0703","authenticated-orcid":false,"given":"Maria","family":"Mazzitelli","sequence":"first","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital , Via Giustiniani, 3, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cozzolino","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua 25128, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[{"name":"Gestione Ambulatoriale Politerapie Outpatient Clinic and Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital , Milan 20157 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pagano","sequence":"additional","affiliation":[{"name":"Gestione Ambulatoriale Politerapie Outpatient Clinic and Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital , Milan 20157 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Reato","sequence":"additional","affiliation":[{"name":"Gestione Ambulatoriale Politerapie Outpatient Clinic and Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital , Milan 20157 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6702-6668","authenticated-orcid":false,"given":"Diego","family":"Ripamonti","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, ASST Papa Giovanni XXIII Hospital , Bergamo 24127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Comi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, ASST Papa Giovanni XXIII Hospital , Bergamo 24127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scaglione","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital , Via Giustiniani, 3, Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mengato","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Unit, Padua University Hospital , Padua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Formica","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Emergency Department, Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-1796","authenticated-orcid":false,"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Disease Unit, AOU Policlinico \u2018P. Giaccone\u2019 , Palermo 90127 ,","place":["Italy"]},{"name":"Infectious Diseases Unit, ARNAS Civico-Di Cristina-Benefratelli Hospital , Palermo 90127 ,","place":["Italy"]},{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties \u2018G D\u2019Alessandro\u2019, University of Palermo , Palermo 90133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Trizzino","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Disease Unit, AOU Policlinico \u2018P. Giaccone\u2019 , Palermo 90127 ,","place":["Italy"]},{"name":"Infectious Diseases Unit, ARNAS Civico-Di Cristina-Benefratelli Hospital , Palermo 90127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Iannone","sequence":"additional","affiliation":[{"name":"Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Farinacci","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Cattelan","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Padua University Hospital , Via Giustiniani, 3, Padua 35128 ,","place":["Italy"]},{"name":"Department of Molecular Medicine, University of Padova , Padua 35128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2025040208380183100_dkaf039-B1","doi-asserted-by":"publisher","first-page":"e0148231","DOI":"10.1371\/journal.pone.0148231","article-title":"Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients","volume":"11","author":"Baril","year":"2016","journal-title":"PLoS One"},{"key":"2025040208380183100_dkaf039-B2","doi-asserted-by":"publisher","first-page":"e28488","DOI":"10.1097\/MD.0000000000028488","article-title":"Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: a retrospective analysis","volume":"100","author":"Mazzitelli","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2025040208380183100_dkaf039-B3","doi-asserted-by":"publisher","first-page":"e29855","DOI":"10.1097\/MD.0000000000029855","article-title":"Real-life use of doravirine in treatment-experienced people living with HIV: a multicenter Italian study","volume":"101","author":"Mazzitelli","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2025040208380183100_dkaf039-B4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/QAI.0000000000003248","article-title":"Doravirine plus integrase strand transfer inhibitors as a 2-drug treatment-switch strategy in people living with HIV: the real-life DORINI multicentric cohort study","volume":"94","author":"Poliseno","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025040208380183100_dkaf039-B5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s15010-023-02075-y","article-title":"The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir","volume":"51","author":"Sammet","year":"2023","journal-title":"Infection"},{"key":"2025040208380183100_dkaf039-B6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/aid.2021.0083","article-title":"Evaluation of a clinic dedicated to people aging with HIV at Chelsea and Westminster hospital: results of a 10-year experience","volume":"38","author":"Pereira","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025040208380183100_dkaf039-B7","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1097\/QAD.0000000000002403","article-title":"Polypharmacy and evaluation of anticholinergic risk in a cohort of elderly people living with HIV","volume":"33","author":"Mazzitelli","year":"2019","journal-title":"AIDS"},{"key":"2025040208380183100_dkaf039-B8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40261-014-0266-2","article-title":"Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks","volume":"35","author":"Quercia","year":"2015","journal-title":"Clin Drug Investig"},{"key":"2025040208380183100_dkaf039-B9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QAI.0000000000002496","article-title":"Review of doravirine resistance patterns identified in participants during clinical development","volume":"85","author":"Martin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025040208380183100_dkaf039-B10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/hiv.13615","article-title":"Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations","volume":"25","author":"Rossotti","year":"2024","journal-title":"HIV Med"},{"key":"2025040208380183100_dkaf039-B11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1060028018798327","article-title":"Association between cognitive tests and antiretroviral medication adherence in older adults with HIV","volume":"53","author":"Caballero","year":"2019","journal-title":"Ann Pharmacother"},{"key":"2025040208380183100_dkaf039-B12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11904-016-0334-8","article-title":"Frailty in HIV: epidemiology, biology, measurement, interventions, and research needs","volume":"13","author":"Piggott","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025040208380183100_dkaf039-B13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1089\/aid.2011.0377","article-title":"Definition of advanced age in HIV infection: looking for an age cut-off","volume":"28","author":"Blanco","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025040208380183100_dkaf039-B14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/eurpub\/cky098","article-title":"Defining and measuring multimorbidity: a systematic review of systematic reviews","volume":"29","author":"Johnston","year":"2019","journal-title":"Eur J Public Health"},{"key":"2025040208380183100_dkaf039-B15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr"},{"key":"2025040208380183100_dkaf039-B16","author":"European AIDS Clinical Society"},{"key":"2025040208380183100_dkaf039-B17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/v15051046","article-title":"Changes in metabolic profile in PLWHIV switching to doravirine-based regimen","volume":"15","author":"Iannone","year":"2023","journal-title":"Viruses"},{"key":"2025040208380183100_dkaf039-B18","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2024.0066","article-title":"Cardiovascular safety of doravirine\/lamivudine\/tenofovir disoproxil fumarate in virologically suppressed PLWHIV: a comparative analysis of CVD scores","author":"Ciccullo","year":"2024","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025040208380183100_dkaf039-B19","doi-asserted-by":"publisher","first-page":"e0065424","DOI":"10.1128\/spectrum.00654-24","article-title":"Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life","volume":"12","author":"Mejias-Trueba","year":"2024","journal-title":"Microbiol Spectr"},{"key":"2025040208380183100_dkaf039-B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/COH.0000000000000709","article-title":"Doravirine: its role in HIV treatment","volume":"17","author":"Stockdale","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2025040208380183100_dkaf039-B21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S2352-4642(23)00164-5","article-title":"Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial","volume":"7","author":"Turkova","year":"2023","journal-title":"Lancet Child Adolesc Health"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/1089\/61820999\/dkaf039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/1089\/61820999\/dkaf039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T05:16:46Z","timestamp":1743571006000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/4\/1089\/8006612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,10]]},"published-print":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf039","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,10]]}}}